Founded in 1995, Covalab is a French biotechnology company renowned for its expertise in antibody engineering. With over three decades of experience, Covalab specializes in the design and development of a wide range of antibodies, including polyclonal, monoclonal, scFv, Fab, VHH, and recombinant antibodies, utilizing advanced techniques such as DNA immunization.

Covalab’s DNA immunization technology provides a distinctive advantage in creating enhanced biological antibodies due to its capability to identify conformational epitopes, including challenging molecules such as transmembrane receptors with post-translational modifications. Covalab has successfully developed more than 20 superior biological antibodies, including those targeting TROP-2, PD-L1, and Nectin-4, which are available for out-licensing for Antibody-Drug Conjugate (ADC) applications.

Covalab’s comprehensive approach includes careful immunogen and animal host selection, rigorous screening processes, and state-of-the-art characterization. Committed to quality, the company holds ISO 9001:2015 certification, reflecting its dedication to excellence in services, products, and R&D.